Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)
Tóm tắt
Nedosiran is an N-acetyl-D-galactosamine (GalNAc)–conjugated RNA interference agent targeting hepatic lactate dehydrogenase (encoded by the LDHA gene), the putative enzyme mediating the final step of oxalate production in all three genetic subtypes of primary hyperoxaluria (PH). This phase I study assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous nedosiran in patients with PH subtype 3 (PH3) and an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2. Single-dose nedosiran 3 mg/kg or placebo was administered in a randomized (2:1), double-blinded manner. Safety/tolerability, 24-h urinary oxalate (Uox) concentrations, and plasma nedosiran concentrations were assessed. The main PD endpoint was the proportion of participants achieving a > 30% decrease from baseline in 24-h Uox at two consecutive visits. Six participants enrolled in and completed the study (nedosiran, n = 4; placebo, n = 2). Nedosiran was well-tolerated and lacked safety concerns. Although the PD response was not met, 24-h Uox excretion declined 24.5% in the nedosiran group and increased 10.5% in the placebo group at Day 85. Three of four nedosiran recipients had a > 30% reduction in 24-h Uox excretion during at least one visit, and one attained near‐normal (i.e., ≥ 0.46 to < 0.60 mmol/24 h; ≥ 1.0 to < 1.3 × upper limit of the normal reference range) 24-h Uox excretion from Day 29 to Day 85. Nedosiran displayed predictable plasma PK. The acceptable safety and trend toward Uox-lowering after single-dose nedosiran treatment enables further clinical development of nedosiran in patients with PH3 who currently have no viable therapeutic options. A plain language summary is available in the supplementary information.
Tài liệu tham khảo
Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369(7):649–658
Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8(8):467–475
Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM et al (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26(10):2559–2570
Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J et al (2021) A report from the European hyperoxaluria consortium (OxalEurope) registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100(3):621–635
Singh P, Viehman JK, Mehta RA, Cogal AG, Hasadsri L, Oglesbee D et al (2021) Clinical characterization of primary hyperoxaluria type 3 in comparison to types 1 and 2: a retrospective cohort study. Nephrol Dial Transplant 37(5):869–875
Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM et al (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6(9):2289–2295
Allard L, Cochat P, Leclerc AL, Cachat F, Fichtner C, De Souza VC et al (2015) Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol 30(10):1807–1813
Lawrence JE, Wattenberg DJ (2020) Primary hyperoxaluria: the patient and caregiver perspective. Clin J Am Soc Nephrol 15(7):909–911
Goldfarb DS, Modersitzki F, Robertson-Lavalle S, Foley C, and Mucha L (2021) Impact of primary hyperoxaluria on patients and caregivers: Healthcare resource use, quality of life, and productivity. Abstract presented at the Academy of Managed Care Pharmacy 2021 Virtual Meeting 12–16
Goldfarb DS, Modersitzki F, Karafilidis J, Li-McLeod J (2023) Healthcare utilization, quality of life, and work productivity associated with primary hyperoxaluria: a cross-sectional web-based US survey. Urolithiasis 51(1):72
Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol 19(3):137–146
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C et al (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87(3):392–399
Fang X, He L, Xu G, Lin H, Xu M, Geng H (2019) Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children. Pediatr Nephrol 34(10):1785–1790
Wang W, Liu Y, Kang L, He R, Song J, Li Y et al (2019) Mutation hot spot region in the HOGA1 gene associated with primary hyperoxaluria type 3 in the Chinese population. Kidney Blood Press Res 44(4):743–753
Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW et al (2022) Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria. Kidney Int 101(3):626–634
Lai C, Pursell N, Gierut J, Saxena U, Zhou W, Dills M et al (2018) Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria. Mol Ther 26(8):1983–1995
Wood KD, Holmes RP, Erbe D, Liebow A, Fargue S, Knight J (2019) Reduction in urinary oxalate excretion in mouse models of primary hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity. Biochim Biophys Acta Mol Basis Dis 1865(9):2203–2209
Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S et al (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103(1):207–217
Levey AS, Stevens LA (2010) Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55(4):622–627
Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA et al (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82(4):445–453
Siener R, Hoppe B, Lohr P, Muller SC, Latz S (2018) Metabolic profile and impact of diet in patients with primary hyperoxaluria. Int Urol Nephrol 50(9):1583–1589
Singh P, Granberg CF, Harris PC, Lieske JC, Licht JH, Weiss A et al (2022) Primary hyperoxaluria type 3 can also result in kidney failure: a case report. Am J Kidney Dis 79(1):125–128
Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R et al (2020) Endpoints for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15(7):1056–1065
Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM et al (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11(1):119–126